ELREXFIO™ (elranatamab-bcmm) has been granted conditional marketing authorization by the European Commission for the treatment of relapsed or refractory multiple myeloma (RRMM) in adults. This approval follows positive findings from the MagnetisMM-3 study, a phase II trial.

ELREXFIO is an innovative subcutaneous treatment that targets B-cell maturation antigen (BCMA). It is ready-to-use and marks the first fixed-dose agent of its kind in Europe. Patients have the option for long-term dosing every other week after an initial 24 weeks of weekly treatment.

The approval paves the way for Pfizer to broaden ELREXFIO's usage in earlier stages of treatment. The company is actively exploring its potential as a standalone therapy and in combination with standard or innovative treatments.

ELREXFIO works by binding to BCMA on myeloma cells and CD3 on T-cells, activating T-cells to eliminate myeloma cells. The European Commission's approval is contingent upon further confirmation of its clinical benefits in additional trials. Read the full press release to learn more.